bakar-labs
(2)
Insamo
Insamo is a Berkeley-based biotechnology company spun out of UC Berkeley that is building membrane-permeable, orally available macrocyclic peptides with antibody-like binding affinity. By pairing machine-learning-driven molecular design with ultra-high-throughput molecular biology and parallel synthetic chemistry, Insamo runs automated design-synthesize-test cycles that generate trillions of proprietary data points - aiming to turn today's injected biologics into pills and to hit drug targets long considered undruggable. The company launched publicly in February 2024 with a $12M seed round led by Playground Global, venBio, and Merck's MRL Ventures Fund.
Timothy Craven
Timothy Craven is the co-founder and CEO of Insamo, a Berkeley-based biotech using machine learning, ultra high-throughput biology, and parallel chemistry to design membrane-permeable, orally available macrocyclic peptides with antibody-like binding. A computational chemist trained in the Nobel-winning lab of David Baker, Craven started Insamo from a grad-school concept with $20,000 of his own money and grew it into a Berkeley-Sydney team backed by a $12M seed from Playground Global, venBio, and Merck's MRL Ventures Fund. His pitch is blunt: turn $30,000 injectable biologics into pills.